Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.

Kamat, Ashish M; Lerner, Seth; Black, Peter; Bellmunt, Joaquim; Dinney, Colin; Hahn, Noah M; O'Donnell, Michael; Quale, Diane Z.

Afiliação

Kamat AM; Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Lerner S; Department of Urologic Oncology, Baylor College of Medicine, TCGA Bladder Cancer, Houston, TX, USA.
Black P; University of British Columbia, Vancouver, BC, Canada.
Bellmunt J; Department of Medicine, Harvard Medical School, Bladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Dinney C; Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Hahn NM; Department of Oncology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
O'Donnell M; Departments of Urology and Urologic Oncology, The University of Iowa, Iowa City, Iowa, IA, USA.
Quale DZ; BCAN (Bladder Cancer Advocacy Network), Baltimore, MD, USA.

Bladder Cancer ; 3(3): 145-146, 2017 Jul 27.

Article em En | MEDLINE | ID: mdl-28824940

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article